|
UY38946A
|
|
PYRROLOPYRIDINES AS KINASE INHIBITORS
|
|
WO2020261156A1
|
|
Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
|
|
WO2020201991A1
|
|
Protein tyrosine phosphatase inhibitors
|
|
WO2020141470A1
|
|
Quinoline compounds as inhibitors of tam and met kinases
|
|
WO2020131674A1
|
|
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
WO2020131627A1
|
|
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
WO2020081848A1
|
|
Protein tyrosine phosphatase inhibitors
|
|
WO2020055672A1
|
|
Fused heterocyclic compounds as ret kinase inhibitors
|
|
UY38349A
|
|
PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
|
|
CA3090748A1
|
|
Methods and combination therapy to treat biliary tract cancer
|
|
US2020339589A1
|
|
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
EP3740486A1
|
|
Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
|
|
EP3740490A1
|
|
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
US2019216923A1
|
|
Methods and combination therapy to treat cancer
|
|
US2019211102A1
|
|
Methods and combination therapy to treat cancer
|
|
WO2019113190A1
|
|
Bicyclic fused pyridine compounds as inhibitors of tam kinases
|
|
AR113804A1
|
|
FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
|
|
CA3080157A1
|
|
Formulations of a macrocyclic trk kinase inhibitor
|
|
TW201922741A
|
|
Crystalline forms
|
|
KR20190126003A
|
|
Macrocyclic Compounds as ROS1 Kinase Inhibitors
|
